[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627418":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":59,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":74,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":85,"overallStatus":88,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Huazhong University of Science and Technology","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"RPC",null,"Patients diagnosed with resectable pancreatic cancer by imaging (CT\u002FMRI)",[13],"Diagnostic Test: CTC",{"label":15,"type":10,"description":16,"interventionNames":17},"BRPC","Patients diagnosed with borderline resectable pancreatic cancer by imaging (CT\u002FMRI)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"LAPC","Patients diagnosed with locally advanced pancreatic cancer by imaging (CT\u002FMRI)",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","CTC","Obtaining portal vein blood and peripheral blood from patients, extracting circulating tumor cells (CTCs) therein, and performing CTC sorting, thereby assisting clinical evaluation of the applicability of neoadjuvant therapy and prognostic assessment for patients with potentially resectable pancreatic cancer.",[15,19,9],[29],{"name":30,"affiliation":31,"role":32},"Bin Cheng","Tongji Hospital","PRINCIPAL_INVESTIGATOR",[34,38],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","+8613986097542","b.cheng@tjh.tjmu.edu.cn",{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},"Qingxiong Ma","13588580316","u202110372@hust.edu.cn",[43],{"facility":44,"status":10,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Tongji Hospital, Tongji Medical College, HUST","Wuhan","Hubei","430030","China","CN",{"type":51,"coordinates":52},"Point",[53,54],114.26667,30.58333,{"lat":54,"lon":53},[57,58],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},{"type":32,"investigatorFullName":30,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"professor","100627418","eus-guided-ctcs--multi-omics-predicting-pancreatic-cancer-recurrence-and-metastases-100627418",false,"NCT07448376","EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases","Exploratory Study on EUS-guided Portal Vein CTCs and Their Subtypes Combined With Multi-omics Detection for Early Warning of Pancreatic Cancer Recurrence and Metastasis","Inclusion Criteria:\n\n1. Patients with solid masses (diameter \\> 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion.\n2. Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT\u002FMRI).\n3. Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy.\n4. Signed informed consent form.\n5. Patients must be able to comply with the trial requirements.\n\nExclusion Criteria:\n\n1. Patients with other active malignant tumors\n2. Patients with coagulation dysfunction (PLT 50,000\u002Fmm3, INR \\> 1.5; roughly estimated, INR \\> 1.5 is approximately equivalent to PT \\> 18 seconds)\n3. Pregnant women\n4. Patients with hemorrhagic diseases\n5. Patients with a history of taking anticoagulant drugs such as aspirin and warfarin in the past week\n6. Patients with absolute contraindications to EUS examination, a history of acute pancreatitis within the past 2 weeks, a history of gastric surgery, pregnancy, severe diseases, or a history of allergy to anesthetics\n7. Patients whose EUS examination was terminated early due to esophageal stenosis, obstruction, large space-occupying lesions, rapid changes in the patient's heart rate or respiratory rate, patient intolerance, or a large amount of food residue, etc.\n8. Patients with known hepatitis C virus infection\n9. Patients with known human immunodeficiency virus (HIV) infection\n10. Patients with imaging examinations, EUS results, etc., suggesting pancreatic cystic space-occupying lesions\n11. Patients who have received radiotherapy or chemotherapy\n12. Patients with incomplete pathological information, unable to make a clear diagnosis, or unable to sign the informed consent form","ALL","18 Years","70 Years",{"count":72,"type":73},20,"ESTIMATED","2 Years","OBSERVATIONAL","The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).",[78,79,80,81,82,83,84],"CTCs","Pancreatic Cancer","Liver Metastases","Relapse","Borderline Resectable Pancreatic Cancer","Resectable Pancreatic Cancers","EUS",[84,25,79,86,87,15,9],"metastases","relapse","NOT_YET_RECRUITING","2026-02-25",{"date":91,"type":92},"2026-03-04","ACTUAL",{"date":94,"type":73},"2026-03-01",{"date":96,"type":73},"2027-12-30",{"name":5,"class":6},1]